Source credit: PubMed / Journal of the International Society of Sports Nutrition – 12-weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin-1 and inflammatory markers in men with obesity: a randomized controlled trial.
Summary: A 12-week randomized controlled trial in 44 men with obesity compared placebo, fisetin alone, training plus placebo, and training plus fisetin. The structured program used eight resistance exercises at 60% of 1RM plus progressive aerobic work, and the combined training-plus-fisetin group showed the biggest drops in fasting glucose, insulin, and HOMA-IR alongside improved inflammation-related markers.
Why it matters for lifters
- Training did the heavy lifting: The paper supports the idea that structured resistance-based training remains the core intervention, while supplementation may only add value around that base.
- Metabolic outcomes can matter as much as aesthetics: For heavier trainees trying to improve gym capacity and health at the same time, better insulin-related markers can be a meaningful training-quality story.
- This is not a blanket supplement endorsement: The participants were obese men in a supervised mixed-training protocol, so the result should not be stretched into a broad claim that fisetin is a proven muscle-building supplement for everyone.
What to watch next
- Watch for larger trials that separate the effects of fisetin from training more cleanly and include trained lifters or women.
- Watch whether future research shows durable changes in body composition, strength, and adherence instead of only short-term biomarker improvements.
- If a supplement claim around inflammation sounds too neat, check whether the study population, training setup, and dose actually match your situation.
Health disclaimer: This article is for informational purposes only and is not medical advice. Obesity, blood sugar, and supplement decisions should be handled with qualified medical guidance, especially if you use prescription medications or have metabolic disease.